Patent ID: 8252821

Claim:
A pharmaceutical composition comprising about 0.1 to 20% of (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, up to about 90% of polyethylene glycol (PEG), up to about 90% of Vitamin E polyethylene glycol succinate (TPGS), about 0.1 to 20% of a crystallization inhibitor member selected from the group consisting of polyvinylpryrrolidone (PVP) and copovidone (PVP-Polyvinyl acetate); and about 0.05 to 5% of citric acid.